(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Presenting Nintendo's New Pastel Satisfaction Con Tones for Switch Gamers: 3 Upscale Choices - 2The biggest black hole breakthroughs of 2025
- 3Man triggers smoke bomb during failed crypto robbery
- 4Euclid space telescope sees gorgeous cosmic cloud | Space photo of the day for Nov. 18, 2025
- 5Jason Kelce opens about wife Kylie Kelce's past pregnancy loss
- A definitive Frozen yogurt Standoff: Which Flavor Rules?
- Truly amazing Palaces: Which Is Your Number one?
- What loving-kindness meditation is and how to practice it in the new year
- Most loved Amusement Park for Small children: Which One Do You Suggest?
- Giude to Best Web based Learning Stage
- AstraZeneca to acquire Modella AI to speed oncology drug research
- US measles cases surpass 2,000, highest in 30 years: CDC
- A volcanic eruption may have catalyzed the plague's arrival in Europe, study suggests
- Ancient meditation practices find new life in modern religious communities across America
